ASX:BOT Botanix Pharmaceuticals (BOT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Botanix Pharmaceuticals Stock (ASX:BOT) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. Get BOT alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.63 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield2.96%Price TargetN/AConsensus RatingN/A Company OverviewBotanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia.Read More… War on Elon Escalates… (Ad)Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. Receive BOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Botanix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BOT Stock News HeadlinesBotanix Pharmaceuticals Passes Key AGM ResolutionsNovember 4 at 4:28 AM | markets.businessinsider.comBotanix Pharmaceuticals Poised for Market Impact with Sofdra LaunchNovember 3 at 8:02 PM | tipranks.comDeFi Coin on Verge of Breakout!Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… November 4, 2024 | Crypto 101 Media (Ad)Botanix Pharmaceuticals Prepares for Sofdra LaunchOctober 28, 2024 | markets.businessinsider.comHere's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn SituationOctober 24, 2024 | finance.yahoo.comBreakeven Is Near for Botanix Pharmaceuticals Limited (ASX:BOT)September 28, 2024 | uk.finance.yahoo.comAlive and Kicking: No sweat as Botanix readies for US launch of its hyperhidrosis treatmentSeptember 17, 2024 | msn.comEvening Wrap: ASX 200 starts September on winning note as big bank rally extends, gold, uranium, and lithium stocks weakerSeptember 2, 2024 | msn.comSee More Headlines BOT Stock Analysis - Frequently Asked Questions How were Botanix Pharmaceuticals' earnings last quarter? Botanix Pharmaceuticals Limited (ASX:BOT) issued its earnings results on Thursday, February, 28th. The company reported ($0.01) EPS for the quarter. What other stocks do shareholders of Botanix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Botanix Pharmaceuticals investors own include Alphabet (GOOG), Meta Platforms (META), Arafura Rare Earths (ARU), Canopy Growth (CGC), Manning & Napier (MN), (STB.TO) (STB) and (YCB) (YCB). Company Calendar Last Earnings2/28/2019Today11/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:BOT CUSIPN/A CIKN/A Webwww.botanixpharma.com Phone+61-8-94820580FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-21.07% Return on Assets-12.74% Debt Debt-to-Equity Ratio0.19 Current Ratio22.21 Quick Ratio1.26 Sales & Book Value Annual Sales$2.07 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.50 Book ValueA$0.06 per share Price / BookN/AMiscellaneous Outstanding Shares1,810,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.71 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (ASX:BOT) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Botanix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Botanix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
